Original article by Damon Kitney
The Australian – Page: 21 : 11-Sep-19
Shares in Melbourne-based stem cell developer Mesoblast rose by over 22 per cent on 10 September after it announced details of a strategic partnership with German drug company Grunenthal. The partnership will see the two companies work to develop and commercialise a cell therapy to threat severe lower back pain, with Mesoblast receiving up to $US150 million ($218.56 million) in upfront and milestone payments prior to the launch of any product developed under the partnership. Billionaire Alex Waislitz, who is one of Mesoblast’s investors, suggests the global potential for a non-opiate product for treating lower back pain could be worth "many billions of dollars" each year.
MESOBLAST LIMITED – ASX MSB, GRUNENTHAL GMBH
Original article by Yolanda Redrup
The Australian Financial Review – Page: 15 : 15-Aug-19
Blood product company CSL released its results for the year to 30 June on 14 August, reporting a net profit after tax of $US1.92 billion ($2.9 billion), up 11 per cent. CSL’s revenue was up by 7.9 per cent to $US8.5 billion, while the company advised that it expected its net profit to exceed $US2 billion in the 2019-20 financial year. CSL CEO Paul Perreault called on its competitors in the global immunoglobulin market to boost their output, or risk demand significantly outweighing supply.
CSL LIMITED – ASX CSL
Original article by Peter Ker
The Australian Financial Review – Page: 14 & 18 : 21-May-19
Incitec Pivot has posted a 2018-19 underlying net profit of $41.9m, compared with $147.1m previously. The company has warned that its fertiliser plant at Gibson Island in Queensland will close by the end of 2019 unless action is taken to address the issue of high gas prices. CEO Jeanne Johns says it will not be viable to keep the plant open until 2022 unless gas prices fall. She has declined to comment on whether the federal government should use the Australian Domestic Gas Security Mechanism to restrict gas export volumes in 2019 and 2020.
INCITEC PIVOT LIMITED – ASX IPL, ENERGYQUEST PTY LTD
Original article by Perry Williams
The Australian – Page: 17 : 18-Apr-19
Directors of DuluxGroup have endorsed a cash offer of $9.80 per share from Japan-based Nippon Paint, which values the deal at $3.8bn. DuluxGroup CEO Patrick Houlihan says the deal will allow the Melbourne-based company to sell its products in more international markets, following the recent launch of its Selleys range in Indonesia. Nippon Paint has stressed that DuluxGroup will retain its branding and leadership team.
DULUXGROUP LIMITED – ASX DLX, NIPPON PAINT, SELLEYS CHEMICAL COMPANY PTY LTD, PARCHEM CONSTRUCTION PRODUCTS PTY LTD, CRAIG AND ROSE, JAPAN POST COMPANY LIMITED, TOLL HOLDINGS LIMITED, MITSUBISHI UFJ FINANCIAL GROUP INCORPORATED, COLONIAL FIRST STATE GLOBAL ASSET MANAGEMENT, ORICA LIMITED – ASX ORI
Original article by Sarah-Jane Tasker
The Australian – Page: 19 : 29-Aug-17
CSL has announced that it will spend $US91 million ($A114 million) on the purchase of US-based biotechnology company Calimmune. CSL executive Andrew Nash says the purchase of Calimmune gives it access to skills and technologies in the area of gene and cell-based therapies that it does not currently have. He said that CSL has had its eye on Calimmune, which has operations in both the US and Australia, for about a year.
CSL LIMITED – ASX CSL, CALIMMUNE INCORPORATED
Original article by Jared Lynch
The Australian Financial Review – Page: 24 : 16-Sep-15
Incitec Pivot CEO James Fazzino says that the US will account for around 50 per cent of the group’s earnings when its ammonia plant in Louisiana is fully operational. He notes that US shale gas prices have fallen sharply since Incitec decided to proceed with the plant, adding that the Louisiana facility provides investors with a "compelling" reason to buy the group’s shares. Fazzino also remains upbeat about the outlook for the Chinese economy.
INCITEC PIVOT LIMITED – ASX IPL, UBS HOLDINGS PTY LTD, CHS, CF INDUSTRIES HOLDINGS INCORPORATED, AUSTRALIA. DEPT OF THE PRIME MINISTER AND CABINET
Original article by Simon Evans
The Australian Financial Review – Page: 8 : 26-Aug-15
Blackmores has reported a rise of 83 per cent in net profit after tax to $A46.6 million for 2014-15. Total sales increased 36 per cent to $A471.6 million. Commenting on the results, Blackmores CEO Christine Holgate said on 25 August 2015 that staff will receive an extra six weeks’ pay as part of a profit-sharing scheme. The final dividend was raised by 63 per cent to $A1.35 a share.
BLACKMORES LIMITED – ASX BKL, BIOCEUTICALS PTY LTD, VITACO HEALTH LIMITED, GOLDMAN SACHS AUSTRALIA PTY LTD, ASX LIMITED – ASX ASX, NUTRA-LIFE HEALTH AND FITNESS AUSTRALIA PTY LTD, HEALTHERIES OF NEW ZEALAND LIMITED, MUSASHI PTY LTD
Original article by John Stensholt
The Australian Financial Review – Page: 29 : 14-May-15
Australian businessman Bruce Mathieson has a 7.46 per cent stake in drug manufacturer Mayne Pharma. The sharp rise in its share price in 2015 has lifted the value of Mathieson’s shareholding to around $A70m. Mayne’s market capitalisation is now almost $A1bn, and Mathieson expects the stock to keep rising. Mathieson is a non-executive director of Mayne.
MAYNE PHARMA GROUP LIMITED – ASX MYX, STANDARD AND POOR’S ASX ALL ORDINARIES INDEX, AUSTRALIAN LEISURE AND HOSPITALITY GROUP LIMITED, WOOLWORTHS LIMITED – ASX WOW, PFD FOOD SERVICES PTY LTD, REECE AUSTRALIA LIMITED – ASX REH, THORNEY INVESTMENTS PTY LTD, FAIRFAX MEDIA LIMITED – ASX FXJ, PFIZER INCORPORATED, WESTERN DESERT RESOURCES LIMITED – ASX WDR
Original article by Jessica Gardner
The Australian Financial Review – Page: 17 : 14-Apr-15
Shares in Mesoblast rose by 24 per cent to $A3.99 on 13 April 2015, after US-based Celgene acquired a stake of around 4.5 per cent in the listed biotechnology group. Celgene paid $A58.5m for 15.3 million shares in Mesoblast, which specialises in the development of stem cell treatments for a range of medical conditions. Celgene will also have first right of refusal to license some of Mesoblast’s products
MESOBLAST LIMITED – ASX MSB, CELGENE INCORPORATED, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, LODGE PARTNERS PTY LTD
Original article by Tim Binsted
The Australian Financial Review – Page: 15 & 20 : 24-Mar-15
Australian-listed explosives group Orica has appointed Alberto Calderon as interim CEO, although chairman Russell Caplan has declined to comment on whether he will be a contender to take on the role permanently. Outgoing CEO Ian Smith was originally slated to remain at the helm during a search for a successor, but the Orica board decided that this was not appropriate. Smith’s management style had attracted some criticism at Orica
ORICA LIMITED – ASX ORI, BHP BILLITON LIMITED – ASX BHP, NEWCREST MINING LIMITED – ASX NCM